MapLight Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $363.45M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Dec 3, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 13, 2026 | After market close | – | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 14, 2026 | After market close | – | $-1.34 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 26, 2026 | Before market open | – | $-2.47 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Dec 4, 2025 | Before market open | – | – | – |
Press releases
Announcements MapLight Therapeutics filed with the SEC
Reported positive results from the potentially registrational Phase 2 ZEPHYR trial of ML-007C-MA in schizophrenia, supporting advancement into a Phase 3 ZEPHYR-2 trial
Material agreement · Results of operations · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
MapLight Therapeutics Announces $150 Million Private Placement Financing
Material agreement · Results of operations · Unregistered share sale · Regulation FD disclosure · EX-99.2 to Form 8-K
Corporate Presentation August 13, 2026
Material agreement · Results of operations · Unregistered share sale · Regulation FD disclosure · EX-99.3 to Form 8-K
ML-007C-MA in Schizophrenia July 27, 2026
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
MapLight Therapeutics Announces Positive Topline Results from Phase 2 ZEPHYR Trial of
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Topline Data from Phase 2 IRIS Trial
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
MapLight Announces Topline Results from Phase 2 IRIS Study for ML-004 in Autism Spectrum Disorder
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
MapLight Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Corporate Presentation May 14, 2026 Exhibit 99.2
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
MapLight Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Corporate Presentation March 26, 2026 Exhibit 99.2
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Corporate Presentation January 09, 2026 Exhibit 99.1
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
MapLight Therapeutics Updates Expected Timing of Topline Results for Ongoing Phase 2 Studies to Q3 2026
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
MapLight Therapeutics Reports Third Quarter Financial Results and
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Corporate Presentation December 4, 2025 Exhibit 99.2
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
FORM OF SHARE PURCHASE AGREEMENT
Unregistered share sale · Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K